Bayesian inference for multivariate survival data with a cure fraction

  • Authors:
  • Ming-Hui Chen;Joseph G. Ibrahim;Debajyoti Sinha

  • Affiliations:
  • Worcester Polytechnic Institute;Harvard School of Public Health and Dana-Farber Cancer Institute;Medical University of South Carolina

  • Venue:
  • Journal of Multivariate Analysis
  • Year:
  • 2002

Quantified Score

Hi-index 0.00

Visualization

Abstract

We develop Bayesian methods for right censored multivariate failure time data for populations with a cure fraction. We propose a new model, called the multivariate cure rate model, and provide a natural motivation and interpretation of it. To create the correlation structure between the failure times, we introduce a frailty term, which is assumed to have a positive stable distribution. The resulting correlation structure induced by the frailty term is quite appealing and leads to a nice characterization of the association between the failure times. Several novel properties of the model are derived. First, conditional on the frailty term, it is shown that the model has a proportional hazards structure with the covariates depending naturally on the cure rate. Second, we establish mathematical relationships between the marginal survivor functions of the multivariate cure rate model and the more standard mixture model for modelling cure rates. With the introduction of latent variables, we show that the new model is computationally appealing, and novel computational Markov chain Monte Carlo (MCMC) methods are developed to sample from the posterior distribution of the parameters. Specifically, we propose a modified version of the collapsed Gibbs technique (J. S. Liu, 1994, J. Amer. Statist. Assoc. 89, 958-966) to sample from the posterior distribution. This development will lead to an efficient Gibbs sampling procedure, which would otherwise be extremely difficult. We characterize the propriety of the joint posterior distribution of the parameters using a class of noninformative improper priors. A real dataset from a melanoma clinical trial is presented to illustrate the methodology.